A. Schoberth

1 ta ish

Technical University of Munich

1. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

   Michael Jäger, A. Schoberth, Peter Ruf +8

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.913705